Search

Search Constraints

You searched for: Author/Creator Rodriguez, Maria A.

Search Results

11. Impact of maintenance rituximab in patients with de novo transformed indolent B cell lymphoma. Issue 12 (14th October 2020)

12. Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B‐cell non‐Hodgkin lymphoma. (8th July 2014)

13. Patterns of use of 18-fluoro-2-deoxy-D-glucose positron emission tomography for initial staging of grade 1–2 follicular lymphoma and its impact on initial treatment strategy in the National Comprehensive Cancer Network Non-Hodgkin Lymphoma Outcomes database. Issue 10 (October 2013)

14. Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell Lymphoma. (13th April 2017)

15. Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell Lymphoma. (May 2017)

16. Pretreatment SUVmax may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FL. Issue 6 (11th May 2020)

17. Rituximab plus hyper‐CVAD alternating with MTX/Ara‐C in patients with newly diagnosed mantle cell lymphoma: 15‐year follow‐up of a phase II study from the MD Anderson Cancer Center. (9th December 2015)

18. Second malignancies in patients with Hodgkin's Lymphoma: Half a century of experience. (July 2022)

19. Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab. Issue 20 (6th August 2013)

20. Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: A comprehensive analysis from the NCCN lymphoma outcomes project. Issue 20 (6th August 2013)